Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics : An Exploratory Study of the Genetics, Pathophysiology, and Natural History of Autoinflammatory Diseases
This is an exploratory natural history protocol that enrolls patients with known or as yet undiagnosed disorders of inflammation. Blood, saliva, or buccal samples will be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, a small number of subjects may undergo skin biopsy, leukapheresis, or bone marrow aspiration and biopsy, and some subjects will be provided standard medical care follow up, with retrospective analysis of the clinical data gathered during follow up. The primary objective is to discover the genetic basis of human disorders of inflammation. The secondary objective is to enumerate immunologic features and genotype-phenotype associations in specific autoinflammatory diseases. The tertiary objective is to describe the clinical features of poorly characterized or newly defined disorders of inflammation. This protocol provided clinical support for the identification of the gene mutated in familial Mediterranean fever (FMF), the discovery of the TNF receptor-associated periodic syndrome (TRAPS), the identification of NLRP3 mutations in the neonatal-onset multisystem inflammatory disease (NOMID), the discovery of the deficiency of the IL-1 receptor antagonist (DIRA), and the proposal of the now widely accepted concept of autoinflammatory disease. During the last decade the protocol has provided the clinical foundation for the discovery of ten more monogenic autoinflammatory diseases, seven of which were previously unrecognized as distinct diseases. The protocol has also permitted numerous studies delineating the mechanisms of autoinflammation and its connections with the human innate immune system. The work catalyzed by this protocol has provided the conceptual basis for a number of targeted therapies. During the next decade the objective will be to utilize cutting edge genomic technologies to further advance discovery..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
ClinicalTrials.gov - (2024) vom: 17. Apr. Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: November 4, 1999, Last downloaded: ClinicalTrials.gov processed this data on April 24, 2024, Last updated: April 24, 2024 |
---|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG000012068 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG000012068 | ||
003 | DE-627 | ||
005 | 20240424010334.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2024 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG000012068 | ||
035 | |a (UBBS_Klinische_Studien)NCT00001373 | ||
035 | |a (UBBS_Klinische_Studien)940105 | ||
035 | |a (UBBS_Klinische_Studien)94-HG-0105 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics |b An Exploratory Study of the Genetics, Pathophysiology, and Natural History of Autoinflammatory Diseases |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: November 4, 1999, Last downloaded: ClinicalTrials.gov processed this data on April 24, 2024, Last updated: April 24, 2024 | ||
520 | |a This is an exploratory natural history protocol that enrolls patients with known or as yet undiagnosed disorders of inflammation. Blood, saliva, or buccal samples will be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, a small number of subjects may undergo skin biopsy, leukapheresis, or bone marrow aspiration and biopsy, and some subjects will be provided standard medical care follow up, with retrospective analysis of the clinical data gathered during follow up. The primary objective is to discover the genetic basis of human disorders of inflammation. The secondary objective is to enumerate immunologic features and genotype-phenotype associations in specific autoinflammatory diseases. The tertiary objective is to describe the clinical features of poorly characterized or newly defined disorders of inflammation. This protocol provided clinical support for the identification of the gene mutated in familial Mediterranean fever (FMF), the discovery of the TNF receptor-associated periodic syndrome (TRAPS), the identification of NLRP3 mutations in the neonatal-onset multisystem inflammatory disease (NOMID), the discovery of the deficiency of the IL-1 receptor antagonist (DIRA), and the proposal of the now widely accepted concept of autoinflammatory disease. During the last decade the protocol has provided the clinical foundation for the discovery of ten more monogenic autoinflammatory diseases, seven of which were previously unrecognized as distinct diseases. The protocol has also permitted numerous studies delineating the mechanisms of autoinflammation and its connections with the human innate immune system. The work catalyzed by this protocol has provided the conceptual basis for a number of targeted therapies. During the next decade the objective will be to utilize cutting edge genomic technologies to further advance discovery. | ||
650 | 2 | |a Brucellosis | |
650 | 2 | |a Genetic Diseases, Inborn | |
650 | 2 | |a Familial Mediterranean Fever | |
650 | 2 | |a Hereditary Autoinflammatory Diseases | |
650 | 2 | |a Fever | |
650 | 2 | |a Hyperthermia | |
650 | 4 | |a Study Type: Observational | |
650 | 4 | |a Recruitment Status: Recruiting | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 17. Apr. |
773 | 1 | 8 | |g year:2024 |g day:17 |g month:04 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT00001373 |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2024 |b 17 |c 04 |